2024 FULL YEAR RESULTS
SUSTAINABLE INNOVATION, WORLD-CLASS SURGEON EDUCATION,
AND AN UNWAVERING COMMITMENT TO IMPROVING PATIENT OUTCOMES
25 March 2025
FRANCESCO SICCARDI
Chief Executive Officer
Highlights - 2024 Full Year Results
Notes
* constant currency
** Alternative Performance Measures: This presentation contains certain financial measures of historical performance that are not defined or specified by IFRS, such as "such as "constant currency", "EBITDA", "Adjusted EBITDA" or "CORE EBITDA", "Adjusted and Normalized EBITDA", "Free Cash Flow", "Adjusted Free Cash Flow", "Adjusted and Normalized Free Cash Flow", "Net Debt" and "Leverage". Reconciliation of these measures as well as "CORE" financial measures is provided in the "Alternative Performance Measures" (APM) section of the 2024 Annual Report. These Alternative Performance Measures (APM) should be regarded as complementary information to, and not as a substitute for the IFRS beginning performance measures. For definitions of APM, together with reconciliations to the most directly reconcilable IFRS line items, please refer section headed "Alternative Performance Measures" of the 2024 Annual Report. The 2024 Annual Report is available athttps://www.medacta.com/EN/financial-reports-and-presentations.
Considerable above market revenue growth
Group revenue CAGR* (2020-2024):
EURm
600
500
400
300
200
100
0
2020
* In constant currency
• 2024 revenue growth* of 16.2% yoy
• Revenue CAGR* (2020-2024) of
18.1%
• Considerable above revenue growth as result of market
• Out-of-the-box thinking innovations to improve patient outcome and healthcare sustainability
• Education and personalised training of surgeons
2021
2022
2023
2024
• Further expansion of sales reps and team
Outstanding growth across all geographies
15.1
40.0
510.8
EURm
16.5%
25.4
16.5%
14.5%
2.3
22.5% Growth rate in constant currency FY 2023
EMEA NA APAC LATAM FY 2024 in cc*
• EMEA and NA: outstanding growth rate* of 16.5%
• APAC: excellent growth rate* in major markets
• LATAM: growth rate* in the low twenties
* in constant currency
593.6
Abbreviations: EMEA: Europe, Middle East and Africa; NA: North America; APAC: Asia Pacific; LATAM: Latin America
590.6
-3.0
FX FY 2024
FY 2024 geographic revenue distribution
LATAM EUR 12.4m, 2%
Clear market outperformance across all business lines
14.1
43.4
510.8
EURm
19.0
8.3%
21.9%
38.8%
6.2
13.4% Growth rate in constant currency
593.6
590.6
-3.0
FY 2024 revenue distribution by business line
* in constant currency ** Extremities includes Shoulder and Sportsmed
Solid growth in Hip
Hip Revenue CAGR* (2020-2024): 12.8%
EURm
250
200
150
100
50
0
2020
Hip
2021
2022
2023
2024
• Growth mainly attributable to Medacta's Anterior Minimally Invasive Surgery (AMIS) platform
• > 2 times market outperformance 2024E** yoy
Notable expansion in Knee
Knee Revenue CAGR* (2020-2024): 22.1%
250
200
EURm
150
100
50
0
2020
2021
2022
2023
2024
Knee
• Outstanding performance due to Medacta's personalised Kinematic Alignment platform MyKA and GMK SpheriKA
• Robust growth across all geographic regions
• > 3 times market outperformance 2024E** yoy
Outstanding growth in Spine
Spine Revenue CAGR* (2020-2024): 17.1%
60
EURm
50
40
30
20
10
0
2020
Spine
2021
2022
2023
2024
• Solid revenue acceleration strongly supported Medacta's technologies, particularly by NextAR Spine
• Particularly strong performance in EMEA
• > 3 times market outperformance 2024E** yoy
by
| Attention: This is an excerpt of the original content. To continue reading it, access the original document here. |